Read the story here. Advertise at Before It's News here.
Profile image
By ProactiveInvestors (Reporter)
Contributor profile | More stories
Story Views
Last hour:
Last 24 hours:

Orgenesis enters collaboration agreement with Tel Aviv Sourasky Medical Center to establish point-of-care cell therapy center

% of readers think this story is Fact. Add your two cents.

Orgenesis (NASDAQ:ORGS) Inc. said it entered into a collaboration agreement with Tel Aviv Sourasky Medical Center to establish a point-of-care (POCare) cell therapy center at the Ichilov Hospital, a leading multidisciplinary healthcare institution in Israel.

The collaboration will initially focus on advancing the clinical development and validation of Orgenesis (NASDAQ:ORGS)’ CD19 CAR-T therapies, including CAR-T derived exosome products, utilizing Orgenesis’ proprietary T-cell culturing and point-of-care processes and systems, the global biotech company said in a statement.

Orgenesis and Tel Aviv Sourasky Medical Center also plan to deploy Orgenesis Mobile Processing Units and Labs (OMPULs) onsite to support joint research and validation activities for advanced cell and gene therapies they develop. OMPULs are multi-purpose, mobile, autonomous good manufacturing practice (GMP) facilities designed to significantly reduce the costs of advanced therapy production and accelerate the clinical development process at the point of care.

“This latest collaboration agreement also expands our POCare network capacity and provides further validation of the importance of our OMPULs,” said Vered Caplan, CEO of Orgenesis.

 “We remain focused on finding exceptional partners like the Tel Aviv Sourasky Medical Center to accelerate development of our broad portfolio of therapies, as well as deploy the OMPULs across our network of leading healthcare facilities and partner companies across the U.S., Europe, Asia, and the Middle East,” he added.

READ: Orgenesis leading the charge at an exciting time for cell therapy

Tel Aviv Sourasky Medical Center’s Deputy Director-General for Research, Development and Innovation, Prof Eli Sprecher said: “This collaboration, utilizing Orgenesis’ POCare platform, reflects our commitment to helping bring potential breakthrough cell therapies to market in a cost effective, high quality and scalable manner.”

Tel Aviv Sourasky Medical Center is the largest acute care facility in Israel, treating about 400,000 patients and hosting 1.8 million patient visits per year.

Story by ProactiveInvestors


Before It’s News® is a community of individuals who report on what’s going on around them, from all around the world.

Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.

"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.

Please Help Support BeforeitsNews by trying our Natural Health Products below!

Order by Phone at 888-809-8385 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Order by Phone at 888-388-7003 or online at M - F 9am to 5pm EST

Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!

HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation

Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.

MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser!  Cleans out toxic buildup with oxygen! 
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover -  Reduces Smart Meter radiation by 96%!  (See Video)

Report abuse


Your Comments
Question   Razz  Sad   Evil  Exclaim  Smile  Redface  Biggrin  Surprised  Eek   Confused   Cool  LOL   Mad   Twisted  Rolleyes   Wink  Idea  Arrow  Neutral  Cry   Mr. Green

Load more ...




Email this story
Email this story

If you really want to ban this commenter, please write down the reason:

If you really want to disable all recommended stories, click on OK button. After that, you will be redirect to your options page.